TSO3 — Investor Presentation (November 2018)
20 slides from TSO3's investor presentation, November 2018
Slide 1: To Create and Deliver the New Standard of Care in Sterile Reprocessing
To Create and Deliver the New Standard of Care in Sterile Reprocessing™ Corporate Presentation | November 2018 1
Slide 2: Important Cautions Regarding Forward Looking Statements and Other Disclosures
Important Cautions Regarding Forward Looking Statements and Other Disclosures The statements contained in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts are forward-looking statements that involve certain risks
Slide 3: Vision and Purpose: A Sterile Device for Every Patient
VISION. PURPOSE. To Create and Deliver The New Standard of Care In Sterile Reprocessing™ A Sterile Device for Every Patient 3
Slide 4: One Disruptive Technology – Two Large Markets
One Disruptive Technology – Two Large Markets Established Base Business Emerging Opportunity Operating Room & Central Sterile Gastrointestinal Supply Department Process/ U.S. ~10,000 Hospitals & Ambulatory Technology ~15M colonoscopies performed Surgery Centers1 annually5 Canada ~1,400 Hospitals2 >5
Slide 5: Breakthrough Technologies: 138 Patents + 49 Patents Pending Worldwide
Breakthrough Technologies /// 138 Patents + 49 Patents Pending Worldwide 1. Insert Room Temperature Instruments Into a Warm Chamber 2. Create a Vacuum and Inject Small Amounts of Vapourized Heated Sterilant Over Time 3. Micro Condensation Forms on the Instruments Condensation Layer Dual Sterilants T
Slide 6: Proven Value Proposition
Proven Value Proposition* New Metric: Cost per Instrument Sterilized, not Cost per Cycle Competition STERIZONE® VP4 Sterilizer Saves up to 50% in Operating Costs 2 STERIZONE® VP4 Sterilizers = 3+ of the Competition in Throughput The Least Expensive Option In the Market Today * Actual customer result
Slide 7: Disruptive Technology for OR Support
Disruptive Technology for OR Support The STERIZONE® VP4 Sterilizer is a dual sterilant, low-temperature sterilization system that uses vaporized hydrogen peroxide (H2O2) and ozone. Features Advantages Benefits • Dual Chemistry • Simple Single Cycle • Lowest Cost per Instrument Operation Sterilized •
Slide 8: Proven Value Proposition – Independent of Customer Size
Proven Value Proposition – Independent of Customer Size Fewer Cycles Fewer Sterilizers Better Efficiency “STERIZONE® VP4 50% less cost per “We had 4 [competitor] Sterilizers, now STERIZONE® VP4 Sterilizer is 3 times instrument sterilized than we have 2 STERIZONE® VP4 Sterilizers.” more efficient tha
Slide 9: Value of a Customer
Value of a Customer Potential Revenue Per US Customer* (Assuming 2 units, 10 Yr Product Life) “Razor” Capital Equipment Sales $200k-$300k 1-4 units per facility Approx. $0.9m-$1.2m Higher-Margin Revenue Proprietary Consumables $20k-$30k/Sterilizer/Year Opportunity per Customer* “Razorblades” Service
Slide 10: Commercialization Approach - CSSD
Commercialization Approach - CSSD LEVERAGE EARLY INCREASE MARKET ESTABLISH STRONG SUPPORT WITH DIRECT ADOPTERS AWARENESS CUSTOMER SALES, CLINICAL AND TARGETING METRICS TECHNICAL PERSONNEL • 59 sterilizers installed in • >5,000 targeted customers • High Use Facilities • Trained in-house personnel US
Slide 11: Sales and Marketing Activities
Sales and Marketing Activities • Sell Direct to End Users • Consultative Sales Approach • Sell With Partners/Agents • System Wide Sales • Strategic Pricing – Lower Capital ASPs in exchange for speed • New Approaches • Cost of Ownership Tools • Digital Ads • Trade Shows TSX:TOS 11
Slide 12: Commercial Activity: As of November 6, 2018
Commercial Activity: As of November 6, 2018 ~5,000 accounts targets in N. America 59 Units Installed in US and Canada >200 opportunities 90 Units Installed or Committed in NA quoted 8 Sales Reps in 8 Territories – going to 11 +10 Units Committed in October 2018 Alone 200 unit goal for 2019 TSX:TOS 1
Slide 13: Endoscopy Sterilization – A Greenfield Opportunity
Endoscopy Sterilization – A Greenfield Opportunity Established Base Business Emerging Opportunity Operating Room & Central Sterile Process/ Gastrointestinal Supply Department U.S. ~10,000 Hospitals & Ambulatory Technology ~15M colonoscopies performed Surgery Centers1 annually5 Canada ~1,400 Hospital
Slide 14: How Shifts Happen: Market Change
How Shifts Happen Patient and Medical Technology Facility Demand Advancement • Patient Safety • STERIZONE® VP4 Sterilizer • Litigation • Cost Reduction = Market Change Regulatory Change • FDA Regulation Advancement • Industry Dialogue and Guidelines TSX:TOS 14
Slide 15: Modernizing GI Endoscope Reprocessing
Modernizing GI Endoscope Reprocessing Decades old processes with only incremental improvement “Despite reprocessing in accordance with US guidelines, viable Old microbes and biologic debris persisted in clinically used [GI] endoscopes, suggesting current reprocessing guidelines are not sufficient to
Slide 16: TSO3 Obtains Expanded Endoscope Clearances
TSO3 Obtains Expanded Endoscope Clearances May 9, 2018 - TSO3 received FDA 510(k) clearance for the terminal sterilization of multi-channeled flexible endoscopes using the Company’s STERIZONE® VP4 Sterilizer • Hospitals can terminally sterilize gastrointestinal endoscopes within the cleared intended
Slide 17: Recent Customer Activity
Recent Customer Activity Altru Health System Improves Patient Care with Expanded Use of Cutting-Edge Sterilization Technology June 15, 2018 - “Being the inaugural facility to offer terminal sterilization of endoscopes using the TSO3 technology, provides our patients with a level of safety above curr
Slide 18: Summary
Next Generation Technology Extensive Patent Portfolio Razor/Razorblade Razor/Razorblade Business Model SUMMARY First- First-to- to-Market FDA- FDA-cleared Device for Terminal Sterilization of Colonoscopes, Duodenoscopes and Gastroscopes Direct Commercialization Strategy Financially Sound TSX:TOS 18
Slide 19: Key Stats (TSX: TOS)
Key Stats (TSX: TOS) /// All Dollars in USD, Unless Noted Otherwise Stock Price (11/23/18) CAD$0.48 52 Week High-Low CAD$2.83-$0.38 Shares Outstanding (mrq) (no warrants) 93.2M Average Daily Volume (90 day) 122,900 Market Capitalization CAD$44.8M Institutional Holdings ~15% Total Revenue (mrq) $0.8M
Slide 20: T Sh,
T Sh,